Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

Expert Opinion on Drug Safety

Volumn 10, Issue 3, 2011, Pages 449-462

  Ruhlmann, Christina H ^a   Herrstedt, Jørn ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

adverse events; aprepitant; CYP3A4; fosaprepitant; MK 0869; neurokinin 1 receptor antagonist; safety; tolerability

Indexed keywords

ANTHRACYCLINE; APREPITANT; CASOPITANT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DEXAMETHASONE; METHYLPREDNISOLONE; ONDANSETRON; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; ASTHENIA; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HICCUP; HUMAN; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; MORPHOLINES; NAUSEA; VOMITING;

EID: 79955423394     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.563235     Document Type: Article

References (64)

1. Coates A, Abraham S, Kaye SB, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8 (Pubitemid 13155858)
2. de Boer-Dennert M, de WR, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-61 (Pubitemid 27434663)
3. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-95 (Pubitemid 26094884)
4. Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1987;1:1198 (Pubitemid 17069302)
5. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian group for antiemetic research. Lancet 1992;340:96-9
6. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-19 (Pubitemid 46606178)
7. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8 (Pubitemid 36676265)
8. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30 (Pubitemid 46179473)
9. Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010;18:423-31
10. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-6 (Pubitemid 43778994)
11. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003;74:150-6 (Pubitemid 36951812)
12. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004;32:1287-92 (Pubitemid 39410914)
13. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44:215-23 (Pubitemid 38233818)
14. Peroutka SJ, Snyder SH. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982;1:658-9 (Pubitemid 12179938)
15. Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983;25(Suppl 1):8-17 (Pubitemid 13195443)
16. Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res 1984;11:277-81
17. Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995;26:911-44
18. Andrews PL, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 1993;32:799-806 (Pubitemid 23227666)
19. Bountra C, Bunce K, Dale T, et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993;249:R3-4 (Pubitemid 23326901)
20. Gardner CJ, Twissell DJ, Dale TJ, et al. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol 1995;116:3158-63 (Pubitemid 26008856)
21. Minami M, Endo T, Yokota H, et al. Effects of CP-99, 994, a tachykinin NK (1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur J Pharmacol 2001;428:215-20 (Pubitemid 33000143)
22. Snider RM, Constantine JW, Lowe JA III, et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991;251:435-7 (Pubitemid 21916907)
23. Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993;250:R5-6
24. Madsen JL, Fuglsang S. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 2008;27:609-15 (Pubitemid 351316787)
25. Huskey SE, Dean BJ, Bakhtiar R, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos 2003;31:785-91 (Pubitemid 36617669)
26. Emend label. Available from: http:// www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search. Label-ApprovalHistory
27. Wu Y, Loper A, Landis E, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 2004;285:135-46 (Pubitemid 39361543)
28. Majumdar AK, Howard L, Goldberg MR, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46:291-300 (Pubitemid 43260316)
29. Bergstrom M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004;55:1007-12 (Pubitemid 38581916)
30. Huskey SE, Dean BJ, Doss GA, et al. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos 2004;32:246-58 (Pubitemid 38176943)
31. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(Suppl 5):v232-43
32. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43:443-69 (Pubitemid 36506147)
33. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67 (Pubitemid 32230878)
34. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300 (Pubitemid 36444075)
35. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 antiemetic trials group. N Engl J Med 1999;340:190-5 (Pubitemid 29063215)
36. Takahashi T, Hoshi E, Takagi M, et al. Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 2010; published online , doi:CAS1689 [pii];10.1111/j.1349-7006.2010.01689.x [doi]
37. van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94:3032-41 (Pubitemid 34547705)
38. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-10 (Pubitemid 38121278)
39. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11 (Pubitemid 46606177)
40. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55 (Pubitemid 41356171)
41. de Jonge ME, Huitema AD, Holtkamp MJ, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56:370-8 (Pubitemid 41095400)
42. Depre M, Van HA, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61:341-6 (Pubitemid 41569307)
43. Majumdar AK, Yan KX, Selverian DV, et al. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. J Clin Pharmacol 2007;47:744-50 (Pubitemid 46800417)
44. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24 (Pubitemid 36776172)
45. Nakade S, Ohno T, Kitagawa J, et al. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 2008;63:75-83
46. Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-19 (Pubitemid 36677284)
47. Loos WJ, de WR, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59:407-12 (Pubitemid 46025528)
48. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55:609-16 (Pubitemid 40674637)
49. Shah AK, Hunt TL, Gallagher SC, Cullen MT Jr. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 2005;21:595-601 (Pubitemid 40676112)
50. Stoch SA, Gargano C, Valentine J, et al. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol 2010; published online, doi:10.1007/s00280-010-1421-y
51. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40:523-30 (Pubitemid 26005556)
52. Howell JE, Szabatura AH, Hatfield SA, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008;14:157-62
53. Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007;18:808-9 (Pubitemid 46523293)
54. Ho H, Yuen C. Aprepitant-associated ifosfamide neurotoxicity. 16th edition. Sage Publications, Ltd; 2010. p. 137-8
55. Jarkowski A III. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm 2008;65:2229-31
56. Jordan K, Kinitz I, Voigt W, et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009;45:1184-7
57. Feuring M, Lee Y, Orlowski LH, et al. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 2003;43:912-17 (Pubitemid 36886111)
58. Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005;45:857-60 (Pubitemid 41416500)
59. Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009;52:242-7
60. Bergman AJ, Marbury T, Fosbinder T, et al. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005;44:637-47 (Pubitemid 40994089)
61. Grunberg SM, Rolski J, Strausz J, et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:549-58
62. Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009;27:5363-9
63. Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009;17:589-94
64. Grunberg SM, Chua D, Devandry S, et al. Evaluation of fosaprepitant in a single dose schedule for prevention of chemotherapy-induced nausea and vomiting: a phase III randomized double-blind study. Support Care Cancer 2010;18(Suppl 3):S79